Navigation Links
Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
Date:9/26/2007

ASHBURN, Va., Sept. 26 /PRNewswire/ -- Innocoll, Inc., a privately-held specialty pharmaceutical company, announced the following status and progress updates regarding its clinical development programs and specialty pharmaceutical operations:

- Three Investigational New Drug (IND) Applications already approved

in 2007.

- GENTAMICIN SURGICAL IMPLANT to commence two US phase 3 multi-centered

clinical trials for the prevention of surgical site infection.

- CollaRx(R) GENTAMICIN TOPICAL to commence a series of phase 2 clinical

trials for the treatment and prevention of infected diabetic foot

ulcers.

- BUPIVACAINE SURGICAL IMPLANT to commence a series of phase 2 clinical

trials for the management of post-operative pain in a variety of soft

tissue and orthopedic surgery models.

- First patient dosing in at least five different clinical trials (three

in phase 2 and two in phase 3) expected before the end of 2007.

- IND submission planned for CollaRx(R) BUPIVACAINE TOPICAL, a new product

opportunity for the management of painful chronic and acute wounds.

- US Launch of CollaGUARD(TM), an advanced wound care product developed by

Innocoll and its first to be launched in the US, is planned for the

fourth quarter 2007.

- European sales and marketing infrastructure sold to EUSA Pharma in

August 2007.

Commenting on the update, Dr. Michael Myers, President and CEO of Innocoll Inc., said, "Our successes over the past few months have established a solid platform on which to build the future growth of the business. We are looking forward to the launch of our first product in the US with CollaGUARD and are poised to commence the clinical development of an exciting portfolio of late- stage pharmaceutical products. According to recent market research performed by L.E.K. Consulting, these three products between them have projected ann
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. XTL Provides Update on Phase I Clinical Trial of XTL-2125
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
6. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
7. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
8. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
9. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... ANGELES , Jan. 23, 2015 A lot of ... best methods for treating  certain illnesses, injuries, or conditions. As ... replace previous treatment methods with ones that they consider to ... hernias, there is not one textbook method of treatment that ...
(Date:1/23/2015)... Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) released ... care leaders and a new study analyzing the impact of increased ... a nationwide coalition working to educate policy makers and the public ... Capitol was focused on how the Iowa ...
(Date:1/23/2015)... 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), ... operable and inoperable solid tumor cancers, announced today that CEO ... Annual Phacilitate Immunotherapy Forum in Washington D.C. ... take place on January 26 at 10:30 a.m. EST at ...
Breaking Medicine Technology:No One-Size-Fits-All Remedy for Hernia Correction 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3
... , , PHOENIX, ... published two new publications on hormone therapies and their effects on ... , Cardiovascular disease caused by atherosclerosis, or the build-up ... of American women--40% of total deaths--and the rate of mortality is ...
... OMER and MIGDAL HA,EMEK, Israel, August 3 ,Medigus ... visualization,medical devices, and Tower Semiconductor, Ltd. (Nasdaq: ... today announced successful,sampling of a new CMOS imager that ... its new medical devices camera; the smallest of its,kind ...
Cached Medicine Technology:TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men 2TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men 3Medigus and Tower Semiconductor Announce World's Smallest Medical Video Camera Based on Advanced CMOS Image Sensor 2Medigus and Tower Semiconductor Announce World's Smallest Medical Video Camera Based on Advanced CMOS Image Sensor 3Medigus and Tower Semiconductor Announce World's Smallest Medical Video Camera Based on Advanced CMOS Image Sensor 4
(Date:1/22/2015)... January 22, 2015 The Incredible Bulk is ... Pakulski to increase lean muscle by up to 30lbs in ... the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. ... is a step-by-step, scientific diet formula that allows the body ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... 2015 A study recently published ... journal Medicine & Science in Sports & Exercise ... help reduce gastrointestinal (GI) problems associated with physical ... in the double-blind, placebo-controlled study took 10 grams ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... maker of the HiArt treatment system for advanced radiation therapy, announced ... linear accelerator manufacturer Chengdu Twin Peak Accelerator Technology Inc., based in ... ... EON) November 4, 2008 -- A linear accelerator (linac) is ...
... 4 With the possibility of,a failed ceasefire ... humanitarian situation in the Democratic Republic of Congo,(DRC), ... of therapeutic food to thousands of displaced civilians ... this crisis could develop into a full-blown catastrophe,if ...
... be Held at 8 a.m. EST -, SHENZHEN, ... (NYSE: NPD ) ("China Nepstar" or the "Company"), ... of directly operated,stores, announced today that the Company will ... before the market opens on,Wednesday, November 26, 2008., ...
... CHAPEL HILL, N.C., Nov. 4 As ... product development,opportunities, fixed-dose combination (FDC) products have ... In an effort to better,understand the development ... a,recent study was conducted by Best Practices, ...
... bond between doctor, parents opens way to discuss habits, ... News) -- Parents are willing to discuss their drinking ... parents for alcoholism and refer them for evaluation or ... commitment to child health, frequent interactions with parents, and ...
... Administrator Sentenced to 70 Months for $11 million ... Ronald,Harris, 58, was sentenced today to 84 months ... was sentenced today to 70 months in,prison for ... scale,HIV infusion fraud schemes, Acting Assistant Attorney General ...
Cached Medicine News:Health News: TomoTherapy Completes Acquisition of Linear Accelerator Manufacturer in China 2Health News:International Medical Corps Continues Delivering Emergency Relief in Democratic Republic of Congo as Potential for Renewed Fighting Threatens to Deepen Crisis 2Health News:China Nepstar Chain Drugstore to Announce Third Quarter 2008 Financial Results on November 26 2Health News:China Nepstar Chain Drugstore to Announce Third Quarter 2008 Financial Results on November 26 3Health News:New Study Provides Benchmarks for Fixed-Dose Combination (FDC) Drug Development 2Health News:Pediatricians Could Help Screen for Alcohol Abuse in Home 2Health News:Miami Physician Sentenced to 84 Months in Prison for $26.2 Million Medicare Fraud 2Health News:Miami Physician Sentenced to 84 Months in Prison for $26.2 Million Medicare Fraud 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: